Plus Therapeutics Announces Reverse Stock Split
AUSTIN, Texas, April 28, 2023 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, today announced that the Company’s Board of Directors has approved a reverse stock split of its shares of common stock at a ratio of 1-for-15. The reverse stock split will become effective at 12:01 a.m. Eastern Time on May 1, 2023, and the Company’s common stock will open for trading on The Nasdaq Capital Market on a post-split basis on May 1, 2023 under the Company’s existing trading symbol, “PSTV.” At such time, the Company’s common stock will also commence trading with a new CUSIP number, 72941H509.
Related news for (PSTV)
- Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
- 24/7 Market News Snapshot 21 October, 2025 – PLUS THERAPEUTICS, Inc. Common Stock (NASDAQ:PSTV)
- MoBot alert highlights: NASDAQ: PSTV, NASDAQ: NERV, NASDAQ: SPWR, NASDAQ: BYND, NASDAQ: TNON (10/21/25 08:00 AM)
- MoBot alert highlights: NYSE: BQ, NYSE: WOLF, NYSE: YCBD, NASDAQ: PSTV, NASDAQ: CYCU (09/29/25 10:00 AM)
- Bitcoin, Biotech, and Biosteel: Innovation Powers the Opening Bell
